United States securities and exchange commission logo

                         December 5, 2023

       Rasmus Holm-Jorgensen
       Chief Financial Officer
       Acrivon Therapeutics, Inc.
       480 Arsenal Way, Suite 100
       Watertown, Massachusetts 02472

                                                        Re: Acrivon
Therapeutics, Inc.
Statement on Form S-3
                                                            Filed December 1,
                                                            File No. 333-275854

       Dear Rasmus Holm-Jorgensen:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Tamika
Sheppard at 202-551-8346 with any questions.


                         Division of Corporation Finance

                         Office of Life Sciences
       cc:                                              Archer Rubin